<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134900</url>
  </required_header>
  <id_info>
    <org_study_id>081002</org_study_id>
    <secondary_id>R01LM009965</secondary_id>
    <nct_id>NCT01134900</nct_id>
  </id_info>
  <brief_title>Achieving Medication Safety During Acute Kidney Injury</brief_title>
  <official_title>Achieving Medication Safety During Acute Kidney Injury: The Impact of Clinical Decision Support and Real-Time Pharmacy Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Library of Medicine (NLM)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The utilization of clinical decision support (CDS) is increasing among healthcare facilities
      which have implemented computerized physician order entry or electronic medical records.
      Formal prospective evaluation of CDS implementations occurs rarely, and misuse or flaws in
      system design are often unrecognized. Retrospective review can identify failures but is too
      late to make critical corrections or initiate redesign efforts. A real-time surveillance
      dashboard for high-alert medications integrates externalized CDS interactions with relevant
      medication ordering, administration, and therapeutic monitoring data. The surveillance view
      of the dashboard displays all currently admitted, eligible patients and provides brief
      demographics with triggering order, laboratory, and CDS failure data to allow prioritization
      of high-risk scenarios. The patient detail view displays a detailed timeline of orders, order
      administrations, laboratory values, and CDS interactions for an individual patient and allows
      users to understand provider actions and patient condition changes occurring in conjunction
      with CDS failures. Clinical pharmacists' use of the dashboard for patient monitoring and
      intervention aims to increase the rate and timeliness of intercepted medication errors
      compared to CPOE-based CDS in the setting of acute kidney injury, which affects patients at
      various points across all hospital units and services and has numerous opportunities for
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Drug Events or Potential Adverse Drug Events</measure>
    <time_frame>Until patient discharge (~2 week average)</time_frame>
    <description>Our primary outcome measured the rate of AKI-related ADEs and pADEs. We defined pADEs as incidents with the potential for injury related to a drug, such as use of a non-steroidal anti-inflammatory drug for at least 24 hours, and ADEs as injuries resulting from the administration of a drug, such as a toxic vancomycin trough level or a bleed after administration of enoxaparin. We measured outcomes after completion of the inpatient encounter (either by death or discharge); pADEs or ADEs occurring after patient discharge were not included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Provider Response</measure>
    <time_frame>Until patient discharge (~2 week average)</time_frame>
    <description>Time from study event to modification or discontinuation of targeted medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <arm_group>
    <arm_group_label>Dashboard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacy Dashboard Review and Intervention</intervention_name>
    <description>Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.</description>
    <arm_group_label>Dashboard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0.5 mg/dl increase or decrease in serum creatinine within 48 hours

          -  Active, recurring order for targeted renally cleared or nephrotoxic medication

        Exclusion Criteria:

          -  Chronic dialysis

          -  Transplant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison B McCoy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at Houston (UTHealth)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josh F Peterson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McCoy AB, Peterson JF, Gadd CS, Danciu I, Waitman LR. A system to improve medication safety in the setting of acute kidney injury: initial provider response. AMIA Annu Symp Proc. 2008 Nov 6:1051.</citation>
    <PMID>18999252</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>January 25, 2012</results_first_submitted>
  <results_first_submitted_qc>January 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2012</results_first_posted>
  <last_update_submitted>January 25, 2012</last_update_submitted>
  <last_update_submitted_qc>January 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Allison McCoy</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Medication Errors</keyword>
  <keyword>Adverse Drug Events</keyword>
  <keyword>Decision Support Systems, Clinical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We performed a randomized, controlled trial during June 1, 2010 through August 31, 2010 at a large academic, tertiary care facility. We included all admitted adult patients who experienced a 0.5 mg/dl change in serum creatinine over 48 hours following an active, recurring order for one or more targeted nephrotoxic or renally cleared medications.</recruitment_details>
      <pre_assignment_details>Patients who were dialyzed prior to the first serum creatinine change event or identified as a dialysis patient through a dialysis flag order, in addition to those admitted to renal transplant, liver transplant, or nephrology services were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dashboard</title>
          <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dashboard</title>
          <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="396"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="16.8"/>
                    <measurement group_id="B2" value="58.3" spread="15.7"/>
                    <measurement group_id="B3" value="59.5" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Drug Events or Potential Adverse Drug Events</title>
        <description>Our primary outcome measured the rate of AKI-related ADEs and pADEs. We defined pADEs as incidents with the potential for injury related to a drug, such as use of a non-steroidal anti-inflammatory drug for at least 24 hours, and ADEs as injuries resulting from the administration of a drug, such as a toxic vancomycin trough level or a bleed after administration of enoxaparin. We measured outcomes after completion of the inpatient encounter (either by death or discharge); pADEs or ADEs occurring after patient discharge were not included in the analysis.</description>
        <time_frame>Until patient discharge (~2 week average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dashboard</title>
            <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Events or Potential Adverse Drug Events</title>
          <description>Our primary outcome measured the rate of AKI-related ADEs and pADEs. We defined pADEs as incidents with the potential for injury related to a drug, such as use of a non-steroidal anti-inflammatory drug for at least 24 hours, and ADEs as injuries resulting from the administration of a drug, such as a toxic vancomycin trough level or a bleed after administration of enoxaparin. We measured outcomes after completion of the inpatient encounter (either by death or discharge); pADEs or ADEs occurring after patient discharge were not included in the analysis.</description>
          <units>Patient-Medication Pairs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-Medication Pairs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1396"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Provider Response</title>
        <description>Time from study event to modification or discontinuation of targeted medication</description>
        <time_frame>Until patient discharge (~2 week average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dashboard</title>
            <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Provider Response</title>
          <description>Time from study event to modification or discontinuation of targeted medication</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-Medication Pairs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1396"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ordered Prior to AKI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="5.61" upper_limit="57.67"/>
                    <measurement group_id="O2" value="27.31" lower_limit="5.98" upper_limit="62.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ordered After AKI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.37" lower_limit="17.9" upper_limit="77.93"/>
                    <measurement group_id="O2" value="43.83" lower_limit="17.62" upper_limit="80.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dashboard</title>
          <description>Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison B. McCoy, PhD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston (UTHealth)</organization>
      <phone>713-500-6931</phone>
      <email>allison.b.mccoy@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

